Memorial Sloan Kettering Cancer Center-ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2023

  1. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

    Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267

  2. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 12, pp. 811-818

2022

  1. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

    Blood Advances, Vol. 6, Núm. 22, pp. 5835-5843

  2. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

2020

  1. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study

    Cancer Medicine, Vol. 9, Núm. 22, pp. 8468-8479

2019

  1. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312

2018

  1. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia

    New England Journal of Medicine, Vol. 378, Núm. 12, pp. 1107-1120

2017

  1. Second primary malignancies in multiple myeloma: An overview and IMWG consensus

    Annals of Oncology, Vol. 28, Núm. 2, pp. 228-245

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2014

  1. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database

    Nature Genetics, Vol. 46, Núm. 2, pp. 107-115

  2. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    The Lancet Oncology, Vol. 15, Núm. 12, pp. e538-e548

2010

  1. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

    Blood, Vol. 116, Núm. 25, pp. 5650-5659